Skip to content
    Clinical Trials

    Tirzepatide for Adolescent Obesity: Findings From the SURMOUNT-ADOLESCENTS Randomized Clinical Trial

    Kelly et alJAMA

    Tirzepatide for Adolescent Obesity: Findings From the SURMOUNT-ADOLESCENTS Randomized Clinical Trial
    In the phase 3 SURMOUNT-ADOLESCENTS randomized clinical trial, once-weekly tirzepatide in combination with a healthy lifestyle intervention led to significant reductions in body mass index (BMI) at 72 weeks compared with placebo in adolescents aged 12 to younger than 18 years. Participants had obesity or were overweight with at least one obesity-related complication.
    The trial randomized 160 participants across 31 medical research centers and hospitals in Canada, the Czech Republic, Israel, Italy, Poland, and the United States in a 2:1 ratio to receive either subcutaneous tirzepatide escalated to the maximum tolerated dose of 5, 10, or 15 mg (n = 109) or placebo (n = 51). At baseline, the mean age was 14.6 years, 61.9% of participants were female, mean body weight was 109.7 kg, and mean BMI was 38.6.
    At week 72, the primary endpoint demonstrated superiority of tirzepatide over placebo, with an 18.5% reduction in BMI in the tirzepatide group compared to a 0.5% increase in the placebo group (estimated treatment difference, -19.0 percentage points [95% CI, -23.9 to -14.1]; P < .001). All 10 key secondary outcomes favored tirzepatide with statistically significant differences, including BMI reductions of at least 5% (79.6% vs 28.5%; risk difference, 51.2 percentage points [95% CI, 36.3-66.1]; P < .001). Gastrointestinal adverse events, mostly mild to moderate, were the most commonly reported adverse events associated with tirzepatide treatment.

    Key Takeaways

    • At week 72, once-weekly tirzepatide resulted in an 18.5% reduction in BMI compared with a 0.5% increase for placebo, reflecting an estimated treatment difference of -19.0 percentage points (95% CI, -23.9 to -14.1; P < .001).
    • A BMI reduction of at least 5% was achieved by 79.6% of adolescents receiving tirzepatide versus 28.5% receiving placebo (risk difference, 51.2 percentage points; 95% CI, 36.3-66.1; P < .001).
    • The most frequent adverse events observed with tirzepatide treatment were gastrointestinal events, which were mostly mild to moderate in severity.